Guidelines Developed for HER2 Testing in Gastroesophageal CA

Share this content:
Guidelines Developed for HER2 Testing in Gastroesophageal CA
Guidelines Developed for HER2 Testing in Gastroesophageal CA

TUESDAY, Nov. 15, 2016 (HealthDay News) -- In guidelines published online Nov. 14 in the Journal of Clinical Oncology, recommendations are presented for optimal HER2 testing in patients with advanced gastroesophageal adenocarcinoma (GEA).

Angela N. Bartley, M.D., from St. Joseph Mercy Hospital in Ann Arbor, Mich., and colleagues established an evidence-based guideline for HER2 testing in patients with GEA. The College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology convened an expert panel that reviewed the literature to develop guidelines for optimal HER2 testing.

The panel proposed 11 recommendations, with strong consensus. These include recommendations that tumor specimens from all patients with advanced GEA be assessed for HER2 status before HER2-targeted therapy initiation. Combination chemotherapy and a HER2-targeted agent should be offered as initial therapy for all patients with HER2-positive advanced GEA. Guidelines are provided for pathologists for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance.

"This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »